Microcap Ledger enGene Therapeutics Inc. $ENGN
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Saint-Laurent
- Fiscal year end
- October 31
- Shares outstanding
- 67,016,316 [10-Q 2026-09-08]
What the company doesAI summary of filing
enGene Therapeutics Inc. is a clinical-stage biotechnology company developing non-viral genetic medicines for delivery to mucosal tissues. The company's lead product candidate, detalimogene voraplasmid, is in Phase 2 clinical trials (LEGEND study) for treatment of non-muscle invasive bladder cancer unresponsive to BCG therapy. Detalimogene uses enGene's proprietary DDX gene delivery platform to deliver genetic cargo directly to bladder tissue. The company is pre-revenue and plans to file a Biologics License Application with the FDA in the second half of 2026, with the goal of independently commercializing detalimogene in the United States while selectively partnering outside the U.S. [10-K 2025-12-22]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 9 months to Jul 2026 | — | −$92.48M | −$78.35M | $41.02M | [10-Q 2026-09-08] |
| FY ended Oct 2025 | — | −$117.30M | −$99.24M | $50.15M | [10-K 2025-12-22] |
| FY ended Oct 2024 | — | −$55.14M | −$48.28M | $173.00M | [10-K 2025-12-22] |
- Quarterly cash burn
- −$26.12M
- Cash runway Estimate
- ~4.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-05 | 50,977,560 | [10-Q 2025-03-10] |
| 2025-06-09 | 51,105,201 | [10-Q 2025-06-12] |
| 2025-09-10 | 51,191,771 | [10-Q 2025-09-11] |
| 2025-12-18 | 66,984,661 | [10-K 2025-12-22] |
| 2026-02-17 | 66,989,466 | [10-K/A 2026-02-19] |
| 2026-03-03 | 66,989,466 | [10-Q 2026-03-09] |
| 2026-06-09 | 66,989,466 | [10-Q 2026-06-15] |
| 2026-09-02 | 67,016,316 | [10-Q 2026-09-08] |
- Shelf registration
- S-3 filed 2026-02-19; declared effective 2026-03-02 [S-3 2026-02-19]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-22 | Grossman William | buy | 5,102 | $1.97 | [4 2026-09-24] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-08 | 10-Q | Quarterly report |
| 2026-09-08 | 8-K | Results of operations |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-11 | 8-K | Other events |
| 2026-07-22 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-17 | 8-K | Regulation FD disclosure |
| 2026-07-16 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-06-18 | 8-K | Exit or disposal costs; Director or officer change |
Alerts for $ENGN
Email me when enGene Therapeutics Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.